Last updated on June 2012
AAML1031, A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443) and Sorafenib (IND# 69896) for Patients with High Allelic Ratio FLT3/ITD
Brief description of study
AAML1031, A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443) and Sorafenib (IND# 69896) for Patients with High Allelic Ratio FLT3/ITD
Detailed Study Description
For more information please visit: http://clinicaltrials.gov/ct2/show/NCT01371981?term=AAML1031&rank=1
Clinical Study Identifier: TX136004
Start Over
Connect »